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Abstract 
Interferon regulatory factor 7 (IRF7) has an essential role in the production of 
type I interferon. Although recent studies detected association of a single 
nucleotide polymorphism (SNP) rs4963128 in PHRF1/KIAA1542, located closely 
to IRF7, and IRF7 rs1131665 (Gln412Arg) with SLE, causal variants have not 
been established. In this study, we resequenced exons and introns of IRF7 to 
screen for all common polymorphisms, and examined whether they were 
associated with SLE in 416 Japanese patients with SLE and 505 healthy controls. 
We also tested whether the association of PHRF1 rs4963128 with SLE was 
replicated in Japanese. None of the IRF7 polymorphisms was associated with 
SLE. PHRF1 rs4963128T was not significantly associated with occurrence of 
SLE either; however, this allele was significantly increased in SLE with anti-Sm 
antibodies (6.8%) as compared with healthy controls (3.1%, P=0.014, odds ratio 
[OR] 2.31) and SLE without anti-Sm antibodies (3.3%, P=0.041, OR 2.12). This 
allele was also increased in SLE with renal disorder (5.1%) as compared with 
those without renal disorder (2.4%, P=0.047, OR 2.17). These results confirmed 
recently reported association of PHRF1 rs4963128T with anti-Sm antibody 
positive SLE in African-American populations, and supported the role of 
PHRF1-IRF7 region in the genetics of SLE.  
 
Keywords systemic lupus erythematosus, genetic studies, polymorphism, 
interferons 
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Introduction 
Interferon regulatory factor 7 (IRF7) is a transcription factor essential for type I 
interferon (IFN) induction1. IRF7 is activated by toll-like receptor (TLR) 7 and 
TLR9 in plasmacytoid dendritic cells and induces a large amount of type I IFN1. 
Type I IFN plays a crucial role in systemic lupus erythematosus (SLE). Serum 
levels of IFN are elevated in SLE patients, and patients treated with IFNα 
sometimes develop features of SLE2. IRF7 is also one of the IFN-inducible 
genes, whose expression in peripheral blood mononuclear cells (PBMCs) is 
upregulated in SLE2,3.  
In 2008, a genome-wide association study (GWAS) in Caucasians identified 
association of rs4963128 located in PHD and ring finger domains 1 (PHRF1), 
also known as KIAA1542, with SLE4. Subsequently, the association was 
confirmed by a replication study in Caucasians5 but not by a GWAS in 
Chinese6.The SNP rs4963128 is located at 23 kb downstream of IRF7 in 
chromosome 11p15.5, and linkage disequilibrium (LD) was observed between 
PHRF1 and IRF7 SNPs in the HapMap samples. Because the function of 
PHRF1 was unknown, the association of rs4963128 was interpreted to be 
caused by LD with IRF7. 
Recently, association of IRF7 SNP rs1131665 (Gln412Arg) with SLE was 
reported in multiple ethnic groups7. In that study, the association of PHRF1 
rs4963128 was not replicated in Asians mainly consisting of Chinese and 
Koreans. Association of IRF7-PHRF1 region SNPs with autoantibody profile has 
also been reported 8.  
Given the functional significance of IRF7 in the type I IFN induction, IRF7 is 
considered to be a strong candidate gene for autoimmune diseases. However, 
although approximately 50 IRF7 polymorphisms are deposited in the dbSNP 
database (http://www.ncbi.nlm.nih.gov/projects/SNP/), the genotype frequency 
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and LD data are not available for many of them. Moreover, to our knowledge, 
resequencing of entire exons and introns of IRF7 has not been reported. In this 
study, we performed polymorphism screening of all exons and introns of IRF7 
gene, followed by an association study of the detected IRF7 polymorphisms as 
well as PHRF1 rs4963128, in Japanese patients with SLE and healthy controls. 
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Materials and methods 
Patients and controls 
An association study was conducted in 416 Japanese patients with SLE (26 
males and 390 females, mean ± SD 43.1 ± 14.1 years) and 505 healthy 
individuals (234 males and 271 females, 34.1 ± 9.8 years), recruited at 
University of Tsukuba, Juntendo University, Sagamihara National Hospital and 
the University of Tokyo. All patients fulfilled the criteria for SLE proposed by the 
American College of Rheumatology (ACR)9.  
Association with clinical characteristics such as renal disorder, presence of 
anti-dsDNA antibody and anti-Sm antibody was also examined. Renal disorder 
was defined according to the ACR criteria9 (proteinuria or cellular cast). 
Anti-dsDNA antibody was measured by ELISA, and the cut off value was 
determined according to the normal range at each institute. Anti-Sm antibody 
was detected using Ouchterlony immunodiffusion. Appearance of precipitin band 
was considered positive. 
This study was reviewed and approved by the research ethics committees of 
University of Tsukuba, Sagamihara National Hospital and Juntendo University. 
Informed consent has been obtained from all participants. 
 
Polymorphism screening and genotyping 
Screening of IRF7 polymorphisms was performed by direct sequencing of 
genomic DNA from 16 SLE patients and 16 healthy controls. Genomic DNA 
sequence was obtained from the GenBank database (accession number: 
NT_009237.18). To amplify the entire IRF7 gene by polymerase chain reaction 
(PCR), 13 primer sets were designed (Supplementary Table 1). Direct 
sequencing was conducted using a BigDye Terminator v3.1 Cycle Sequencing 
kit on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster City, 
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CA). 
Three polymorphisms, rs10902179A>G, rs3832720 GGAGGC repeats (3 or 4 
repeats), and rs55917943 A indel, were selected as tag polymorphisms based 
on the screening data with the criteria of minor allele frequency (MAF) ≥0.05 and 
an r2 threshold of 0.8 (Figure 1a). These three polymorphic sites as well as two 
IRF7 nonsynonymous SNPs rs1061502A>G (Lys179Glu) and rs1131665A>G 
(Gln412Arg) were tested for association in 416 SLE patients and 505 healthy 
controls. In addition, PHRF1 rs4963128 was also included in the analysis. 
Genotyping of the SNPs rs10902179 and rs55917943 were genotyped using 
Custom TaqMan SNP Genotyping Assays (ABI). Genotyping of rs1061502 was 
performed by TaqMan SNP Genotyping Assay (C___1611549_10) (ABI). The 
SNPs rs3832720, rs1131665 and rs4963128 were genotyped by direct 
sequencing using primers IRF7-2F-2R, IRF7-11F-11R and PHRF1-F-R 
(Supplementary Table 1), respectively. 
 
Statistical analysis 
Statistical significance of differences in allele frequencies between cases and 
controls was tested using χ2 test with 2×2 contingency tables. When one or more 
cells in the contingency tables contained the variables of 5 or less, Fisher’s exact 
test was applied. Pairwise r2 values were calculated using Haploview version 4.0 
software (Broad Institute, Cambridge, MA).  
Power calculation was conducted based on the allele frequencies in Japanese 
and the sample size in this study (416 cases and 505 controls)10. This study had 
>80% power to detect association with the genotype relative risk of ≥2.31 for 
rs1061502 and rs1131665, 1.71 for rs10902179, 1.37 for rs3832720, 1.33 for 
rs55917943, and 1.92 for rs4963128. 
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Results 
Polymorphism screening and an association study of IRF7 gene 
Due to lack of publicly available genotype frequency and LD data of IRF7 
polymorphisms, we screened polymorphisms in all exons and introns of IRF7 by 
resequencing genomic DNA from 16 Japanese SLE patients and 16 healthy 
individuals. The polymorphisms detected by resequencing and LD structure are 
demonstrated in Figure 1a. Three tag polymorphisms selected based on the 
allele frequency and LD status in the screening samples, rs10902179A/G, 
rs3832720 GGAGGC repeats (3 or 4 repeats) and rs55917943A indel, as well as 
two low-frequency nonsynonymous SNPs, Lys179Glu (rs1061502A>G) and 
Gln412Arg (rs1131665A>G), were tested for association in 416 Japanese SLE 
patients and 505 healthy controls.  
Call rate was 100% for these five polymorphisms, and none of the genotype 
distribution was significantly deviated from Hardy–Weinberg equilibrium in the 
cases and controls (P>0.05). LD between each IRF7 polymorphism in 505 
healthy individuals is shown in Figure 1b. The two nonsynonymous SNPs, 
rs1061502 and rs1131665, were in absolute LD with each other (r2=1). A novel 
30 bp indel was detected in intron 8 (position 553742-553713 [NT_009237.18]), 
whose call rate was 92.5% and was excluded from the analysis. 
As shown in Table 1, association of IRF7 SNPs with occurrence of SLE was not 
detected in Japanese. 
 
An association study of PHRF1 rs4963128 
We next examined whether the previously reported association of PHRF1 
rs4963128 with SLE in Caucasians was replicated in Japanese. The allele 
frequency of rs4963128T in our Japanese 505 healthy controls (3.1%) was 
substantially lower than in the Caucasians (33.7%)4, which was consistent with 
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the frequency data of rs4963128T in the HapMap database (CEU: 32.9%, JPT: 
2.2%, CHB: 4.5%). The SNP rs4963128 was in moderate LD (r2=0.54) with IRF7 
nonsynonymous SNPs (rs1061502/rs1131665) (Figure 1b). In agreement with 
the previous reports from Asian populations6,7, no significant association of 
rs4963128 with SLE was observed in Japanese (Table 1). 
 
Association of SLE subset with polymorphisms in IRF7 and PHRF1 
We next investigated whether polymorphisms in IRF7 and PHRF1 were 
associated with SLE subsets such as presence of renal disorder, anti-Sm 
antibodies and anti-dsDNA antibodies (Table 2). When the allele frequencies 
were compared between each subset of SLE and healthy controls, significant 
association of rs4963128T was observed in SLE with anti-Sm antibodies 
(case-control analysis). The association was confirmed when the SLE patients 
with anti-Sm antibodies and those without were compared (case-only analysis). 
Association of rs4963128T with renal disorder was also detected in case-only 
comparisons. On the other hand, association of IRF7 with the SLE subsets was 
not detected.  
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Discussion 
IRF7 plays a crucial role in the induction of type I IFN. Given the significance of 
type I IFN in SLE, IRF7 has been thought to be a strong candidate susceptibility 
gene to SLE, which gained strong support by the recent studies that reported the 
association of PHRF1 rs4963128 located closely to IRF74,5, as well as IRF7 
rs1131665 (Gln412Arg), with SLE7. To examine whether IRF7 primarily 
contributes to susceptibility to SLE and the association of rs4963128 can be 
explained by LD with common polymorphisms in IRF7, we performed 
polymorphism screening of IRF7 by resequencing, and conducted an 
association study of IRF7 polymorphisms as well as PHRF1 rs4963128 in 
Japanese. However, evidence for association with the occurrence of SLE was 
observed neither for rs4963128 nor IRF7 SNPs. Analysis for gene-gene 
interaction between rs4963128 and each SLE risk alleles established in 
Japanese (HLA-DRB1, IRF5, STAT4, BLK, FCGR2B, TNFAIP3, TNIP1 and 
TNFSF13) failed to show significant interaction (data not shown). 
With respect to PHRF1 rs4963128, our observation was consistent with the 
report by Fu et al.7 and GWAS in Chinese6, which failed to detect the association 
between rs4963128 and occurrence of SLE in Asians. On the other hand, in 
contrast to our observation, association of IRF7 rs1131665 (Gln412Arg) has 
been reported in Asian populations, the majority of which were Chinese and 
Koreans7. This lack of agreement does not appear to be explained by the 
difference in the population allele frequency of 412Arg, which was 1.7% in this 
study and 2.9% in the previous study of the Asian populations7. Another 
possibility is the lack of sufficient detection power for the low frequency variants. 
In rs1131665, the sample size of this study provided 80% power to detect 
associations only when the genotype relative risk was ≥2.31. However, in this 
study, although not statistically significant, opposite tendency towards increase 
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of 412Arg rather than the previously reported 412Gln7 was observed in SLE 
(412Arg, SLE: 1.9%, control: 1.7%). Thus, it appears unlikely that the lack of 
association is explained only by the insufficient statistical power. At this point, it 
appears that the difference in the association reflects slight differences in the 
genetic background among the Japanese, Korean and Chinese populations11. In 
the future, association of IRF7 with SLE should be examined using an 
independent larger sample set. 
Although the association of PHRF1 rs4963128 with occurrence of SLE was not 
detected, we found that rs4963128 was associated with the presence of anti-Sm 
antibodies and renal disorder in SLE patients. In agreement with our results, 
Salloum et al. reported the association of anti-Sm antibodies with rs4963128 in 
African Americans8. In addition, they showed that among the SLE patients with 
anti-Sm antibodies, only the patients carrying rs4963128T exhibited higher 
IFNα activity. Their observations suggested that rs4963128T is not only involved 
in induction of anti-Sm antibodies, but also in upregulation of IFNα under the 
presence of anti-Sm antibodies. Preferential association of PHRF1 with patients 
with renal disorder in our study is in line with the previously reported association 
between renal disorder and presence of anti-Sm antibody12 and IFN signature13.  
Anti-Sm antibodies are directed against small nuclear ribonucleoproteins. It is 
assumed that interaction of the RNA-protein complex with specific B cell 
receptors on the surface of B cells may lead to the transport of the complex to 
endosomes, where RNA binds to TLR7 and may induce activation of IRF7, 
which eventually leads to B cell activation and production of anti-Sm antibodies14. 
Therefore, the lack of causative variations within IRF7 was an unexpected 
finding. Because our current study which resequenced 16 cases and 16 controls 
focused on common variants, this study does not exclude the possibility that rare 
variants of IRF7 might play a role. In addition, according to the HapMap 
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database, LD with rs4963128 encompasses the entire IRF7 gene and extends to 
the upstream region of IRF7, which has the opposite direction of transcription to 
PHRF1. Therefore, although association of polymorphisms in IRF7 was not 
detected in this study, the possibility that rs4963128T, or other allele(s) in the 
regulatory region of IRF7 which is in LD with rs4963128T, may be associated 
with anti-Sm antibodies through the effects on IRF7 expression cannot be 
excluded.  
Finally, it is also possible that PHRF1 might be causally involved in the 
pathogenesis of SLE. PHRF1 was initially identified by screening of an adult 
brain cDNA library, and its expression was observed in heart, brain, lung, liver, 
skeletal muscle, kidney, pancreas, spleen, testis and ovary15; however, the 
function of PHRF1 has not been elucidated yet. Further studies are required to 
elucidate the molecular mechanisms of PHRF1-IRF7 region association with 
SLE with anti-Sm antibody and renal diseases. 
In conclusion, resequencing of the Japanese SLE and controls did not detect 
common polymorphisms associated with SLE within IRF7 exons and introns. 
However, we independently replicated the association of PHRF1 SNP 
rs4963128T with anti-Sm antibody recently reported in the African-American 
populations, and also detected association with the presence of renal disorder. 
These results supported the role of PHRF1-IRF7 region in the genetics of clinical 
manifestations of SLE. 
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Table 1. An sssociation study of polymorphisms in IRF7 and PHRF1/KIAA1542 with susceptibility to SLE in a Japanese population. 
 
  SLE (n=416) Controls (n=505) P OR (95%CI) 
IRF7     
 rs10902179 G 34 (4.1) 50 (5.0) 0.38 0.82 (0.52-1.28) 
 rs3832720 (GGAGGC)3  169 (20.3) 209 (20.7) 0.84 0.98 (0.78-1.23) 
 rs1061502G(179Glu) 16 (1.9) 17 (1.7) 0.70 1.15 (0.58-2.28) 
 rs1131665G (412Arg) 16 (1.9) 17 (1.7) 0.70 1.15 (0.58-2.28) 
 rs55917943 A ins 253 (30.4) 304 (30.1) 0.89 1.01 (0.83-1.24) 
PHRF1/KIAA1542     
 rs4963128T 32 (3.8) 31 (3.1) 0.36 1.26 (0.76-2.09) 
 
OR: odds ratio, 95%CI: confidence interval. Allele frequencies are shown in parentheses (%). 
Association was tested by chi-square analysis using 2×2 contingency tables. 
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Table 2. An association study of PHRF1/KIAA1542 -IRF7 region SNPs with clinical characteristics of SLE in a Japanese population. 
  Case-control analysis  Case-only analysis (+ versus -) 
 allele frequency n (%) P OR (95%CI)  P OR (95%CI) 
IRF7 rs1061502G(179Glu), rs1131665G (412Arg)    
 SLE    
anti-Sm Abs + (n=88) 5 (2.8) 0.36a 1.71(0.62-4.69)  0.38 a 1.57(0.54-4.57) 
anti-Sm Abs - (n=300) 11 (1.8) 0.82 1.09(0.51-2.34)   ref 
  anti-dsDNA Abs + (n=324) 16 (2.5) 0.26 1.48(0.74-2.95)  0.092 a 7.54(0.45-126.4) 
anti-dsDNA Abs - (n=72) 0 (0.0) 0.25 a 0.20(0.01-3.28)   ref 
  renal disorder + (n=224) 12 (2.7) 0.21 1.61(0.76-3.40)  0.13 a 2.52(0.81-7.88) 
renal disorder - (n=185) 4 (1.1) 0.62 a 0.64(0.21-1.91)   ref 
Control (n=505) 17 (1.7)  ref    
       
PHRF1/KIAA1542 rs4963128T      
 SLE      
anti-Sm Abs + (n=88) 12 (6.8) 0.014 2.31(1.16-4.59)  0.041 2.12(1.02-4.43) 
anti-Sm Abs - (n=300) 20 (3.3) 0.77 1.09(0.61-1.93)   ref 
  anti-dsDNA Abs + (n=324) 29 (4.5) 0.13 1.48(0.88-2.48)  0.24 a 2.20(0.66-7.33) 
anti-dsDNA Abs - (n=72) 3 (2.1) 0.79 a 0.67(0.20-2.23)   ref 
  renal disorder + (n=224) 23 (5.1) 0.054 1.71(0.98-2.97)  0.047 2.17(0.99-4.75) 
renal disorder - (n=185) 9 (2.4) 0.53 0.79(0.37-1.67)   ref 
Control (n=505) 31 (3.1)  ref    
OR: odds ratio, 95%CI: confidence interval, Abs: antibodies. Allele frequencies are shown in parentheses (%). 
Association was tested by chi-square analysis or Fisher’s exact test using 2×2 contingency tables.  
a Fisher’s exact test was employed.
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Figure Legends 
Figure 1. Polymorphisms and linkage disequilibrium status of PHRF-IRF7 region in 
Japanese. 
(a) IRF7 polymorphisms detected by resequencing in the screening samples and 
pairwise r2 values based on data in the 16 SLE and 16 healthy individuals used for 
resequencing. The polymorphisms genotyped for association study are shown in 
boldface. Two novel polymorphisms, T/G SNP at position 553672 and 30bp indel 
polymorphism at position 553742-553713 of chromosome 11 (NT_009237.18), were 
identified and shown by asterisk. 
(b) Pairwise r2 values among the five IRF7 polymorphisms and PHRF1 rs4963128 
based on data in 505 Japanese healthy individuals. 

Supplementary Table 1. Primers used in this study. 
Fragment (chromosomal position*) Primer name Primer sequence 
PHRF1 (529375 - 529709) PHRF1 F 5’-CAGGGTGCTTGATGTGTTGT-3’ 
 PHRF1 R 5’-CACAGAGCTACCCATGCTTTC-3’ 
   
IRF7-1 (556087-555820) IRF7-1 F 5’-CCTCCACTCCTCCCTACTCC-3’ 
 IRF7-1 R 5’-CCCAGCTCTTGGCTCTACC-3’ 
IRF7-2 (555990-555583) IRF7-2 F 5’-GCCTGGCCACCATAAAAGC-3’ 
 IRF7-2 R 5’-CGCACACATGAAGTCACAGG-3’ 
IRF7-3 (555721-555334) IRF7-3 F 5’-GAAGCGCCACTGTTTAGGTTT-3’ 
 IRF7-3 R 5’-CGGGCTCTTACCTCTCAGGA-3’ 
IRF7-4 (555480-555087) IRF7-4 F 5’-CTGTGACACCTGGCCACAC-3’ 
 IRF7-4 R 5’-GGGTCCCCACCTTGAAGA-3’ 
IRF7-5 (555192-554753) IRF7-5 F 5’-CTGCAGTGGCTGGACGAG-3’ 
 IRF7-5 R 5’-AAGCAGGACGAATGCCAAC-3’ 
IRF7-6 (554875-554452) IRF7-6 F 5’-GTGATGCTGCGGGATAACTC-3’ 
 IRF7-6 R 5’-AGAGGCAGGCAGAGAGAAGG-3’ 
IRF7-7 (554575-554167) IRF7-7 F 5’-CTCTGGTGTCGGGGCCTA-3’ 
 IRF7-7 R 5’-CCCACACCTCCAGCACACG-3’ 
IRF7-8 (554268-553866) IRF7-8 F 5’-TCTGCTGACAGCGTCATGG-3’ 
 IRF7-8 R 5’-CTGCATCCGGAAGGGAAT-3’ 
IRF7-9 (553965-553456) IRF7-9 F 5’-CGGCACTAACGACAGGTGA-3’ 
 IRF7-9 R 5’-TACCTGCTGGGGGTCTGTG-3’ 
IRF7-10 (553616-553243) IRF7-10 F 5’-CACAGCTTGGTCTCCACACA-3’ 
 IRF7-10 R 5’-ACAGTTCCGAGGCAGCAG-3’ 
IRF7-11 (553412-553003) IRF7-11 F 5’-GCTACACGGAGGAACTGCTG-3’ 
 IRF7-11 R 5’-ACCAGGACCAGGCTCTTCTC-3’ 
IRF7-12 (553130-552721) IRF7-12 F 5’-TCCCCTTCTTCAGAGCTGGT-3’ 
 IRF7-12 R 5’-CTGAGGCTGCTGCTATCCAG-3’ 
IRF7-13 (552907-552424) IRF7-13 F 5’-GGCCATACACCGGGTCAC-3’ 
 IRF7-13 R 5’-TTGGCTGTGATGTGTGTGGT-3’ 
*Chromosomal positions were based on the chromosome 11 genomic sequence obtained 
from the GenBank database (accession number: NT_009237.18). 
